TEVA PHARMACEUTICAL INDUSTRIES LTD

For the period ended Dec 31, 2024. Filed Feb 5, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Feb 5, 2025

TEVA$42.97+0.8%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Statements of income

(U.S. dollars in millions, except share and per share data)

	Year ended December 31,
	2024	2023	2022
Net revenues	$16,544	$15,846	$14,925
Cost of sales	8,481	8,200	7,952
Gross profit	8,064	7,645	6,973
Research and development expenses, net	998	953	838
Selling and marketing expenses	2,541	2,336	2,265
General and administrative expenses	1,161	1,162	1,180
Intangible assets impairments	251	350	355
Goodwill impairment	1,280	700	2,045
Other asset impairments, restructuring and other items	1,388	718	512
Legal settlements and loss contingencies	761	1,043	2,082
Other loss (income)	(14)	(49)	(107)
Operating income (loss)	(303)	433	(2,197)
Financial expenses – net	981	1,057	966
Income (loss) before income taxes	(1,284)	(624)	(3,163)
Income taxes (benefit)	676	(7)	(643)
Share in (profits) losses of associated companies – net	(1)	(2)	(21)
Net income (loss)	(1,959)	(615)	(2,499)
Net income (loss) attributable to non-controlling interests	(320)	(56)	(53)
Net income (loss) attributable to Teva	(1,639)	(559)	(2,446)
Earnings (loss) per share attributable to ordinary shareholders:
Basic	$(1.45)	$(0.50)	$(2.20)
Diluted	$(1.45)	$(0.50)	$(2.20)
Weighted average number of shares (in millions):
Basic	1,131	1,119	1,110
Diluted	1,131	1,119	1,110

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.